Alnylam Pharmaceuticals (ALNY) Insider Trading & Ownership $246.27 -2.89 (-1.16%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Alnylam Pharmaceuticals (NASDAQ:ALNY) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage1.50%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)8Amount OfInsider Selling(Last 12 Months)$31.42 M Get ALNY Insider Trade Alerts Want to know when executives and insiders are buying or selling Alnylam Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ALNY Insider Buying and Selling by Quarter Alnylam Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/12/2024Pushkal GargCMOSell1,752$251.00$439,752.00 11/26/2024Pushkal GargCMOSell1,682$250.98$422,148.36 11/26/2024Tolga TangulerEVPSell1,469$250.98$368,689.62 11/26/2024Yvonne GreenstreetCEOSell5,219$250.98$1,309,864.62 8/20/2024Yvonne GreenstreetCEOSell15,000$280.00$4,200,000.00 8/6/2024Dennis A AusielloDirectorSell20,250$262.00$5,305,500.00 8/1/2024Yvonne GreenstreetCEOSell15,148$270.00$4,089,960.00 7/11/2024Yvonne GreenstreetCEOSell7,093$261.00$1,851,273.00 6/25/2024Jeffrey V PoultonCFOSell1,605$231.00$370,755.00 6/25/2024Kevin Joseph FitzgeraldEVPSell1,198$230.99$276,726.02 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 6/25/2024Pushkal GargCMOSell2,103$230.99$485,771.97 6/25/2024Yvonne GreenstreetCEOSell8,301$230.99$1,917,447.99 6/24/2024David E I PyottDirectorSell32,450$220.69$7,161,390.50 5/29/2024Amy W SchulmanDirectorSell21,700$148.60$3,224,620.00 (Data available from 1/1/2013 forward) ALNY Insider Trading Activity - Frequently Asked Questions Who is on Alnylam Pharmaceuticals's Insider Roster? The list of insiders at Alnylam Pharmaceuticals includes Akshay Vaishnaw, Amy W Schulman, David E I Pyott, Dennis A Ausiello, Indrani Lall Franchini, Jeffrey V Poulton, Kevin Joseph Fitzgerald, Michael W Bonney, Pushkal Garg, Steven M Paul, Tolga Tanguler, and Yvonne Greenstreet. Learn more on insiders at ALNY. What percentage of Alnylam Pharmaceuticals stock is owned by insiders? 1.50% of Alnylam Pharmaceuticals stock is owned by insiders. Learn more on ALNY's insider holdings. Which Alnylam Pharmaceuticals insiders have been selling company stock? The following insiders have sold ALNY shares in the last 24 months: Akshay Vaishnaw ($465,459.28), Amy W Schulman ($3,224,620.00), David E I Pyott ($7,161,390.50), Dennis A Ausiello ($5,305,500.00), Indrani Lall Franchini ($1,113,566.75), Jeffrey V Poulton ($1,203,910.43), Kevin Joseph Fitzgerald ($276,726.02), Michael W Bonney ($5,850,000.00), Pushkal Garg ($6,729,235.93), Tolga Tanguler ($655,904.46), and Yvonne Greenstreet ($15,604,341.91). How much insider selling is happening at Alnylam Pharmaceuticals? Insiders have sold a total of 217,660 Alnylam Pharmaceuticals shares in the last 24 months for a total of $47,590,655.28 sold. Which members of congress are trading Alnylam Pharmaceuticals? Josh Gottheimer (D-NJ) has sold shares of Alnylam Pharmaceuticals in the last year totaling $8,000. Alnylam Pharmaceuticals Key ExecutivesDr. Yvonne L. Greenstreet M.B.A. (Age 61)MBChB, CEO & Director Compensation: $2.15MMr. Jeffrey V. Poulton M.B.A. (Age 56)CFO & Executive VP Compensation: $1.05MDr. Akshay K. Vaishnaw M.D. (Age 61)Ph.D., Chief Innovation Officer & Member of the Scientific Advisory Board Compensation: $1.12MDr. Pushkal P. Garg M.D. (Age 56)Chief Medical Officer and Executive VP of Development & Medical Affairs Compensation: $1.06MMr. Tolga Tanguler M.B.A. (Age 51)Executive VP & Chief Commercial Officer Compensation: $971.3k1 recent tradesMr. Timothy J. MainesChief Technical Operations & Quality OfficerDr. Kevin Joseph Fitzgerald Ph.D. (Age 55)Senior VP, Head of Research & Chief Scientific Officer Ms. Christine Regan Lindenboom (Age 43)Senior VP of Investor Relations & Corporate Communications Mr. Piyush Sharma J.D.Chief Ethics & Compliance OfficerMr. Evan Lippman M.B.A.Chief Corporate Development & Strategy Officer More Insider Trading Tools from MarketBeat Related Companies Gilead Sciences Insider Trades Vertex Pharmaceuticals Insider Trades Regeneron Pharmaceuticals Insider Trades Biogen Insider Trades United Therapeutics Insider Trades Neurocrine Biosciences Insider Trades Incyte Insider Trades BioMarin Pharmaceutical Insider Trades Exact Sciences Insider Trades Exelixis Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Strong Capital Returns and Insider Buying SignalsZymeworks in Focus for Insider Activity: Catalysts AheadInsiders Are Loading Up: 3 Key Stock Picks for InvestorsInsiders Are Selling, But These 3 Stocks Are Must-Buys3 Stocks That Wall Street Insiders Can’t Stop Buying This page (NASDAQ:ALNY) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredThe #1 Stock for Trump’s Second Term?Imagine how much money you could make if you bought all of the top performing stocks during Trump's second ter...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
